Aromasin tablets 25mg, No. 30

widespread breast cancer in women in natural or induced postmenopausal women with the progression of the disease against the background of antiestrogen therapy, as well as with the progression of the disease after repeated use of various types of hormonal therapy;

adjuvant therapy for early breast cancer in postmenopausal women with estrogen-positive receptors or with unknown receptor status, after completion of 2-3 years of initial adjuvant therapy with tamoxifen, in order to reduce the risk of relapses (distant or regional), as well as contralateral breast cancer.

Inside, preferably after meals. Adults and elderly patients - 25 mg 1 time per day.

In patients with early breast cancer, drug treatment is recommended to continue until the total duration of sequential adjuvant hormonal therapy reaches 5 years. Treatment of patients with advanced breast cancer is long-term. If signs of tumor progression appear or if contralateral breast cancer develops, treatment with AromasinЃ should be discontinued.

No dose adjustment is required in patients with hepatic or renal impairment.

Not recommended for use in children.

in a blister, 15 pcs.; in a cardboard box 1, 2 or 6 blisters.

hypersensitivity to exemestane or to any other component of the drug;

premenopausal endocrine status;

pregnancy and lactation;

childhood.

With caution - impaired liver or kidney function.